Regenerative Medicine Designed For You
BIONA Pharma develops First-in-Class targeted gene therapy and next-generation mRNA drugs for personalized application. Our medicine activates the heart's own resident stem cells to regenerate damaged myocardial tissue – no transplants, no donors, no aggressive interventions.
The Science of Regeneration
Standard cardiac treatments address symptoms. BIONA Pharma targets the root cause – activating your body's innate repair mechanisms using precision gene therapy tuned to your individual biology, biomarkers, and genetic profile.
Apoptomic Analysis
Our research pioneered a new omic science – apoptomics – which studies the RNA-containing apoptotic bodies released by dying cells. These packages carry the molecular instructions that tell resident stem cells to differentiate into new heart muscle. We have learned to read and replicate this code.
Precision Formulation
Our microRNA-based therapeutic formulated to mimic the natural signals (apoptotic bodies) that activate cardiac stem cells residing inside mature cardiomyocytes. The drug acts at the molecular level, matched to specific biological pathways – not a one-size-fits-all protocol.
In Situ Regeneration
Our treatment triggers regeneration where it is needed – directly inside the damaged myocardium. A single resident cardiac stem cell can release up to 200 new cardiac precursors. No external cell transplants. No donors. The body heals itself, guided by our therapy.
Join the Web3 regeneration ecosystem
Get BIONA TokensFrom your biology to your medicine – a seamless journey to personalized cardiac care
Our personalized drug development pipeline translates individual biological data into a targeted therapeutic protocol, from first profiling to real-world outcome monitoring
Patient Profiling
Comprehensive biomarker analysis combined with genetic sequencing, clinical history, and lifestyle data to build a complete bioinformational profile. This becomes the foundation of your personalized treatment trajectory.
Apoptomic Mapping
AI-assisted analysis of your apoptotic body profile and cardiac biomarkers identifies the specific molecular signals governing your myocardial stem cell activity –pinpointing the optimal therapeutic targets unique to your biology.
Personalized Drug Formulation
Formulated as a personalized high-tech medicinal product, with composition and dosage calibrated to your individual genetic markers, biomarker panel, and clinical data. Each preparation is bespoke.
Pharmaceutical-Grade Synthesis & QC
Production follows strict pharmaceutical-grade standards at every stage, with rigorous quality control throughout synthesis. BIONA Pharma is building its own contract development and manufacturing capacity (CDMO) to maintain full control over product integrity.
Administration Protocol
Personalized dosing schedule administered within the Human Regeneration Center or through accredited partner clinics. All protocols are integrated into the BIONA digital platform, enabling continuous remote follow-up and real-time adjustment.
Outcome Tracking
Real-time biomarker monitoring and longitudinal data capture measure therapeutic response at every stage. Results feed back into the BIONA AI platform, continuously validating efficacy in real-world conditions and improving future protocols.
Pharma Development Timeline
Our path from preclinical discovery to global personalized medicine deployment
Scientific Council & Protocol Preparation
Formation of the scientific advisory board (12 professors, 33 international consultants). Development and approval of preclinical research protocols. Ethics Committee approval, Informed Consent documentation, and IP/patent strategy finalized.
Preclinical Studies (DKI) & Validation
Apoptomics research and preclinical studies underway. Protocol validation, data collection, and preparation of the pilot industrial manufacturing setup for scale-up. Partner clinics integrated into the research network.
Clinical Trial Launch – UAE
Entering clinical trials in the UAE. First human subjects receive the microRNA-based cardiac regeneration therapy. Clinical data integrated into the BIONA research platform. Results from preclinical phase published.
Human Regeneration Center Launch & Real-World Cases
The Dubai Human Regeneration Center opens and begins delivering personalized programs. First real patient cases documented and published. CDMO supply chain tested and scaled. White-label partner clinic model rolled out.
New Therapeutic Directions & Global Expansion
Expansion of the regenerative drug pipeline beyond cardiac – additional organ regeneration targets explored based on apoptomics findings. Regulatory approvals pursued in EU and Southeast Asian markets. New clinical trial programs initiated on new markets. The DeSci Token for Human Regeneration.
Ready to Dive Deeper?
Download the whitepaper, connect your wallet, and join the BIONA ecosystem today.